Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
Retrieved on:
Tuesday, June 14, 2022
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, ALT, Science, Frankfurt Stock Exchange, Precision medicine, Company, Biology, Phosphorylation, MAD, MDAX, Pharmacokinetics, Plasma, Adenosine, Nasdaq, Volunteering, Multimedia, Therapy, EVO, SAD, Brain, Male, ISIN, Patient, Neoplasm, BID, Private Securities Litigation Reform Act, Immune system, AST, Drug discovery, PD, CNS, CREB, Cancer, Safety, Pharmaceutical industry, Vaccine, A2A, Evotec
One of the studys primary goals was to inform the optimal starting dose for EXS-21546 for the Phase 1b/2 study in cancer patients.
Key Points:
- One of the studys primary goals was to inform the optimal starting dose for EXS-21546 for the Phase 1b/2 study in cancer patients.
- Inhibition of A2A receptor signaling was sustained over the BID dosing period, demonstrating a level of lasting target engagement.
- The Company expects to share additional data from this Phase 1a study at future medical meetings.
- The Phase 1 study was a three-part study in male healthy volunteers to assess the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of EXS-21546.